GALECTIN THERAPEUTICS INC
GALT evidence brief
What we can confirm
- BioSniper Score:
- 3.5 / 10
- Market Cap:
- $394.3M
- Lead Asset:
- belapectin (Phase 2/Phase 3)
What it means
What to watch
Prepared research question
What matters most for GALT—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · GALT
Galectin Therapeutics Inc. (GALT) is a clinical-stage biopharmaceutical company developing belapectin, a galectin-3 inhibitor, for fibrotic disease and cancer, with a focus on MASH cirrhosis and portal hypertension.
Key risk: Phase 3 trial failure risk
BioSniper Score
Based on 4 of 6 signals
Financial data as of Jun 30, 2026.
Tracking 1 pipeline candidate · 2 clinical trials for GALECTIN THERAPEUTICS INC.
Galectin Therapeutics Inc. (GALT) is a clinical-stage biopharmaceutical company developing belapectin, a galectin-3 inhibitor, for fibrotic disease and cancer, with a focus on MASH cirrhosis and portal hypertension.
- Galectin Therapeutics is a clinical-stage biopharmaceutical company focused on developing therapeutics that target galectin proteins for fibrotic disease, cancer, and other diseases [sec_mda · as of 2026-03-31].
- The company's lead drug candidate, belapectin, is a proprietary, patented compound derived from natural, plant-based starting materials that binds to and inhibits galectin-3 [sec_mda · as of 2026-08-14].
- As of June 30, 2026, the company reported cash & equivalents of $13.3M, a net loss of -$9.1M, and negative shareholders' equity of -$138.6M [sec].
- In June 2026, Galectin reached an agreement with the FDA on the primary endpoint and regulatory path forward for a potential Phase 3 trial of belapectin in MASH cirrhosis and portal hypertension [news · published 2026-06-23].
- The company intends to file the Phase 3 protocol in Q3 2026 and is actively exploring strategic and financial partnership opportunities to support continued development and commercialization of belapectin [news · published 2026-06-23].
What works
- The company has reached a key regulatory milestone, securing FDA agreement on the primary endpoint and regulatory path for a Phase 3 trial of belapectin in MASH cirrhosis and portal hypertension, which de-risks the clinical pathway [news · published 2026-06-23].
- Belapectin has shown favorable results in a pharmacokinetic study in subjects with hepatic impairment (NCT04332432), which became fully enrolled in February 2022 [sec_mda · as of 2026-08-14].
- The company leverages cost-effective and efficient drug development through established relationships with outside sources for preclinical, clinical, and manufacturing expertise [sec_mda · as of 2026-08-14].
What to weigh
- The company has a significant accumulated deficit, with negative shareholders' equity of -$138.6M as of June 30, 2026, indicating a history of losses exceeding capital [sec].
- Cash & equivalents of $13.3M as of June 30, 2026, may be limited relative to the costs of a Phase 3 trial, and the company is actively seeking strategic and financial partnerships to support continued development [news · published 2026-06-23].
- The company faces extensive and costly FDA regulation, and there is a risk that belapectin may fail to demonstrate efficacy and safety in ongoing or future human trials [sec_mda · as of 2025-11-14].
- The company has limited trading volume and concentrated stock ownership, which could contribute to stock price volatility [sec_mda · as of 2025-11-14].
From the filings
Quoted directly from source documents.
FDA agreement on Phase 3 path for belapectin
“Galectin has reached agreement with the FDA on the primary endpoint and regulatory path forward for the potential full approval of belapectin”
News · June 23, 2026
Belapectin is a galectin-3 inhibitor derived from plant materials
“Belapectin is a proprietary, patented compound derived from natural, plant-based, starting materials, which following chemical processing, exhibits the properties of binding to and inhibiting galectin-3.”
SEC MD&A · August 14, 2026
Company is exploring partnerships for belapectin development
“Company intends to file the Phase 3 protocol in Q3 2026 and is actively exploring strategic and financial partnership opportunities to support the continued development and commercialization of belapectin”
News · June 23, 2026
Catalyst timeline
- 2020-06-16 · Phase 1 Start: Pharmacokinetic Study of Belapectin in Subjects with Hepatic Impairment — This single-dose, open-label study examined belapectin's pharmacokinetics in subjects with normal and impaired hepatic function.
- 2020-06-25 · Phase 3 Start: Study for Prevention of Esophageal Varices in NASH Cirrhosis — This seamless, adaptive Phase 2b/3 trial evaluates belapectin for preventing esophageal varices in NASH cirrhosis patients.
Risks & what to watch (4)›
Key risks
- Phase 3 trial failure risk — Belapectin may fail to demonstrate efficacy and safety in the planned Phase 3 trial, which could halt development [sec_mda · as of 2025-11-14].
- Insufficient cash runway — Cash of $13.3M as of June 30, 2026, may be insufficient to fund a Phase 3 trial without new partnerships or financing [sec].
- Regulatory and competitive pressures — The company is subject to extensive FDA regulation and faces competition in the biotechnology industry, which could impact market position [sec_mda · as of 2025-11-14].
- Stock liquidity and volatility — Limited trading volume and concentrated ownership of stock may lead to price volatility [sec_mda · as of 2025-11-14].
What to watch
- Filing of the Phase 3 protocol for belapectin in MASH cirrhosis and portal hypertension, expected in Q3 2026 [news · published 2026-06-23].
- Announcement of strategic or financial partnerships to support belapectin's continued development and commercialization [news · published 2026-06-23].
- Future financial reports to monitor cash position and net loss trends, given the negative shareholders' equity of -$138.6M as of June 30, 2026 [sec].
- Any new clinical data from the ongoing NAVIGATE trial or the hepatic impairment study (NCT04332432) that could impact regulatory or partnership discussions [news · published 2025-11-14].
Sources: Catalysts · News · SEC MD&A · Generated October 13, 2026 · How we verify sources →
Run GALECTIN THERAPEUTICS INC through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available GALECTIN THERAPEUTICS INC facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 4 of 6 signals · derived from public data
Cash runway data unavailable
Net income -$9M
Lead: Phase 2/Phase 3
1 candidate
No upcoming catalysts tracked
0 buys · 8 sells (180d)
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
98
Total value held
$37.8M
| Holder | Shares | Value |
|---|---|---|
| vanguard capital management llc | 1,966,542 | $5.5M |
| marshall wace, llp | 1,219,912 | $3.4M |
| osaic holdings, inc. | 1,122,670 | $3.1M |
| blackrock, inc. | 799,237 | $2.2M |
| millennium management llc | 798,434 | $2.2M |
| wealthspire advisors, llc | 721,788 | $2.0M |
| geode capital management, llc | 612,786 | $1.7M |
| susquehanna international group, llp | 555,702 | $1.6M |
| two sigma investments, lp | 467,063 | $1.3M |
| commonwealth equity services, llc | 367,113 | $1.0M |
Showing top 10 of 98 institutional holders of GALECTIN THERAPEUTICS INC. Open the full 13F history after sign-in.
Short Interest
as of May 21, 2026- % of float
- 17.6%
- Days to cover
- 21.9
- Shares short
- 7,388,749
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
GALT short interestGovernance
Frequently asked questions
What is the AI investment thesis for GALECTIN THERAPEUTICS INC?
Galectin Therapeutics Inc. (GALT) is a clinical-stage biopharmaceutical company developing belapectin, a galectin-3 inhibitor, for fibrotic disease and cancer, with a focus on MASH cirrhosis and portal hypertension.
What is GALECTIN THERAPEUTICS INC's lead drug candidate?
GALECTIN THERAPEUTICS INC's most advanced tracked candidate is belapectin (Phase 2/Phase 3) for Hepatic Impairment; Prevention of Esophageal Varices.
Who is the CEO of GALECTIN THERAPEUTICS INC?
Mr. Joel Lewis CPA is the chief executive officer of GALECTIN THERAPEUTICS INC (GALT).
Where is GALECTIN THERAPEUTICS INC headquartered?
GALECTIN THERAPEUTICS INC (GALT) is headquartered in Norcross, GA, United States.
What therapeutic areas does GALECTIN THERAPEUTICS INC focus on?
GALECTIN THERAPEUTICS INC develops therapies across Oncology, Infectious Disease, Metabolic, Gastroenterology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.